comprehensive -WSS

comprehensive

author：focus 2025-09-30 15:22:21 - browse：3197

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

WSS

Humana cuts profit projections as Medicare Advantage costs soar

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

With competition flaring, obesity drug hits goal in liver disease study

Elizabeth Holmes banned from government health programs

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The Harvard botanist who searched for psychedelics in the Amazon

Walensky prepares to leave CDC — and Congress — behind

A new nitrogen execution bill also undermines medical licensing

Guidelines to prevent youth baseball injuries need more muscle

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Medical leaders decry Supreme Court decision on affirmative action

The surgeon had a dilemma only a Nazi medical text could resolve

focus

Obesity drugs seen as possible treatment for liver disease MASH

STAT readers on older presidents, polypills, Medicare, and more

New brain studies show LSD's effects on the brain in full color

He's a Nobel laureate. Critics say he was misleading on Covid

The tragedy of Johnson & Johnson’s Covid vaccine

AI generated plenty of interest at JPM but not a lot of trust

focus

focus

leisure time

focus